[1]张丽娜,王凯,范国锋,等.M6A去甲基化酶FTO在脑胶质瘤中的表达及其与病人预后的关系[J].中国临床神经外科杂志,2023,28(01):34-37.[doi:10.13798/j.issn.1009-153X.2023.01.010]
　ZHANG Li-na,WANG Kai,FAN Guo-feng,et al.Expression of m6A demethylase FTO in glioma tissues and its relationship with patients' prognoses[J].,2023,28(01):34-37.[doi:10.13798/j.issn.1009-153X.2023.01.010]
点击复制

M6A去甲基化酶FTO在脑胶质瘤中的表达及其与病人预后的关系()

《中国临床神经外科杂志》[ISSN:1009-153X/CN:42-1603/TN]

卷:
28
期数:
2023年01期
页码:
34-37
栏目:
论著
出版日期:
2023-01-25

文章信息/Info

Title:
Expression of m6A demethylase FTO in glioma tissues and its relationship with patients' prognoses
文章编号:
1009-153X（2023）01-0034-04
作者:
张丽娜; 王凯; 范国锋; 秦虎
841100乌鲁木齐，新疆医科大学第一附属医院神经外科（张丽娜、王凯、范国锋、秦虎）
Author(s):
ZHANG Li-na;  WANG Kai;  FAN Guo-feng;  QIN Hu
Department of Neurosurgery, The First Affiliated Hospital of Xinjiang Medical University, Urumqi 841100, China
关键词:
脑胶质瘤; 去甲基化酶; 肥胖相关蛋白; 生存预后
Keywords:
Glioma;  Demethylase;  Fat mass and obesity-associated protein;  Prognosis
分类号:
R739.41;Q786
DOI:
10.13798/j.issn.1009-153X.2023.01.010
文献标志码:
A
摘要:
目的 探讨6-甲基腺嘌呤（m6A）去甲基化酶肥胖相关蛋白（FTO）在脑胶质瘤中的表达及其与病人生存预后的关系。方法 选取2015年1月至2017年8月手术切除的脑胶质瘤标本84例（WHOⅡ级24例，Ⅲ级14例，Ⅳ级46例）和颅脑损伤内减压术中获取的非肿瘤脑组织40例为对照。免疫印迹法和免疫组化法检测组织FTO表达水平。胶质瘤病人随访截止2022年8月，计算总生存期。结果 免疫组化染色显示，WHO分级Ⅱ、Ⅲ、Ⅳ级脑胶质瘤组织FTO高表达率分别为20.83%（5/24）、50.00%（7/14）、73.91%（34/46），均明显高于非肿瘤脑组织[10%（4/40）；P<0.05]；而且，WHO分级Ⅳ级胶质瘤FTO过表达率明显高于Ⅱ级胶质瘤（P<0.05）。免疫印迹法检查结果显示脑胶质瘤组织FTO蛋白表达水平明显高于非肿瘤脑组织（P<0.05）。截止随访结束，脑胶质瘤死亡30例，其中高表达组死亡18例，低表达组死亡12例。多因素logistic回归分析显示，FTO高表达是胶质瘤预后不良的独立危险因素（OR=3.794；95% CI 1.164~5.108；P<0.001）。生存曲线分析显示，FTO高表达组中位总体生存期较低表达组明显缩短（P<0.001）。结论 脑胶质瘤组织m6A去甲基化酶FTO呈高表达，与病人不良生存预后有关。
Abstract:
Objective To investigate the expression of 6-methyladenine (m6A) demethylase obesity-related protein (FTO) in glioma tissues and its relationship with patients' survival prognoses. Methods The expression of FTO was detected in glioma tissues obtained from 84 glioma patients who underwent surgery from January 2015 to August 2017 (24 cases of WHO grade Ⅱ, 14 cases of WHO grade Ⅲ, 46 cases of Ⅳ) and in non-tumor brain tissue obtained from 40 patients with traumatic brain injury who underwent decompression by western blotting and immunohistochemistry, respectively. The glioma patients were followed up until August 2022, and the overall survival time was calculated. Results Immunohistochemical staining showed that the high expression rates of FTO in glioma tissue of WHO grade Ⅱ, Ⅲ, and Ⅳ were 20.83% (5/24), 50.00% (7/14) and 73.91% (34/46), respectively, which were significantly higher than that [10% (4/40)]in non-tumor brain tissue (P<0.05). In addition, the high expression rate of FTO in WHO grade Ⅳ gliomas was significantly higher than that in grade Ⅱ gliomas (P<0.05). Western blotting showed that the expression level of FTO protein in glioma tissues was significantly higher than that in non-tumor brain tissues (P<0.05). By the end of follow-up, 30 glioma patients died, including 18 patients with high expression of FTO and 12 with low expression. Multivariate logistic regression analysis showed that high expression of FTO was an independent risk factor for poor prognosis of glioma patients (OR=3.794; 95% CI 1.164~5.108; P<0.001). Survival curve analysis showed that the median overall survival time was significantly shorter in the patients with high FTO expression than the patients with low FTO expression (P<0.001). Conclusions The m6A demethylase FTO is highly expressed in glioma tissues, which is associated with a poor survival prognosis of glioma patients.

参考文献/References:

[1]Xu S, Tang L, Li X, et al. Immunotherapy for glioma: current management and future application [J]. Cancer Lett, 2020, 476: 1-12.
[2]Deng LJ, Deng WQ, Fan SR, et al. m6A modification: recent advances, anticancer targeted drug discovery and beyond [J]. Mol Cancer, 2022, 21(1): 52.
[3]An Y, Duan H. The role of m6A RNA methylation in cancer metabolism [J]. Mol Cancer, 2022, 21(1): 14.
[4]Chen DH, Zhang JG, Wu CX, et al. Non-coding RNA m6A modification in cancer: mechanisms and therapeutic targets [J]. Front Cell Dev Biol, 2021, 9: 778582.
[5]Shimura T, Kandimalla R, Okugawa Y, et al. Novel evidence for m(6)A methylation regulators as prognostic biomarkers and FTO as a potential therapeutic target in gastric cancer [J]. Br J Cancer, 2022, 126(2): 228-237.
[6]Wang J, Qiao Y, Sun M, et al. FTO promotes colorectal cancer progression and chemotherapy resistance via demethy-lating G6PD/PARP1 [J]. Clin Transl Med, 2022, 12(3): e772.
[7]Duan X, Yang L, Wang L, et al. m6A demethylase FTO promotes tumor progression via regulation of lipid metabolism in esophageal cancer [J]. Cell Biosci, 2022, 12(1): 60.
[8]Xiao L, Li X, Mu Z, et al. FTO inhibition enhances the antitumor effect of temozolomide by targeting MYC-miR-155/23a cluster-MXI1 feedback circuit in glioma [J]. Cancer Res, 2020, 80(18): 3945-3958.
[9]Zhang S, Zhao S, Qi Y, et al. SPI1-induced downregulation of FTO promotes GBM progression by regulating pri-miR-10a processing in an m6A-dependent manner [J]. Mol Ther Nucleic Acids, 2022, 27: 699-717.
[10]张朋肖，吴红记，甘　宁，等. 人脑胶质瘤FAM46A表达与病人预后的关系[J]. 中国临床神经外科杂志，2022，27（3）：171-173.
[11]Pan T, Wu F, Li L, et al. The role m(6)A RNA methylation is CNS development and glioma pathogenesis [J]. Mol Brain, 2021, 14(1): 119.
[12]Lan N, Lu Y, Zhang Y, et al. FTO--a common genetic basis for obesity and cancer [J]. Front Genet, 2020, 11: 559138.
[13]Fan J, Zhuo Z, Chen G, et al. FTO gene polymorphisms and hepatoblastoma susceptibility among Chinese children [J]. Cell Cycle, 2022, 21(14): 1512-1518.
[14]Hua RX, Fu W, Lin A, et al. Role of FTO gene polymorphisms in Wilms tumor predisposition: a five-center case-control study [J]. J Gene Med, 2021, 23(8): e3348.
[15]Su R, Dong L, Li Y, et al. Targeting FTO suppresses cancer stem cell maintenance and immune evasion [J]. Cancer Cell,2020, 38(1): 79-96.e11.
[16]Xu Y, Ye S, Zhang N, et al. The FTO/miR-181b-3p/ARL5B signaling pathway regulates cell migration and invasion in breast cancer [J]. Cancer Commun (Lond), 2020, 40(10): 484-500.
[17]Li Y, Su R, Deng X, et al. FTO in cancer: functions, molecular mechanisms, and therapeutic implications [J]. Trends Cancer, 2022, 8(7): 598-614.
[18]Huang J, Sun W, Wang Z, et al. FTO suppresses glycolysis and growth of papillary thyroid cancer via decreasing stability of APOE mRNA in an N6-methyladenosine-dependent manner [J]. J Exp Clin Cancer Res, 2022, 41(1): 42.
[19]Su R, Dong L, Li C, et al. R-2HG exhibits anti-tumor activity by targeting FTO/m(6)A/MYC/CEBPA signaling [J]. Cell, 2018, 172(1-2): 90-105.e123.
[20]Zhou Q, Liu J, Quan J, et al. lncRNAs as potential molecular biomarkers for the clinicopathology and prognosis of glioma: a systematic review and meta-analysis [J]. Gene, 2018, 668: 77-86.
[21]Cong P, Wu T, Huang X, et al. Identification of the role and clinical prognostic value of target genes of m6A RNA methylation regulators in glioma [J]. Front Cell Dev Biol, 2021, 9: 709022.
[22]Tao N, Wen T, Li T, et al. Interaction between m6A methy-lation and noncoding RNA in glioma [J]. Cell Death Discov, 2022, 8(1): 283.

相似文献/References:

[1]付　锴　江普查　宫　睿　王　伟.表达VASH1基因的人脑胶质瘤U-87MG细胞对化疗药物敏感性的变化[J].中国临床神经外科杂志,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
　FU Kai,JIANG Pu-cha,GONG Rui,et al.Effect of lentiviral vector-mediated VASH1 gene on chemosensitivity of human glioma U-87MG cells[J].,2016,(01):34.[doi:10.13798/j.issn.1009-153X.2016.01.012]
[2]崔焕喜,柳　琛.多模态MRI、神经导航和超声在脑胶质瘤术中的应用[J].中国临床神经外科杂志,2016,(11):721.[doi:10.13798/j.issn.1009-153X.2016.11.027]
[3]闫　珊　徐善才.多学科护理照顾模式对脑胶质瘤术后病人自我护理能力的影响[J].中国临床神经外科杂志,2017,(05):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
　YAN Shan,XU Shan-cai..Effects of multi-subjects nursing care model on self-care ability in patients with brain glioma after operation[J].,2017,(01):352.[doi:10.13798/j.issn.1009-153X.2017.05.026]
[4]罗似亮　夏之柏.脑胶质瘤病人脑脊液Midkine表达的临床意义[J].中国临床神经外科杂志,2017,(06):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
　LUO Si-liang,XIA Zhi-bo..Clinical meanings of midkine expression in cerebrospinal fluid of patients with gliomas[J].,2017,(01):416.[doi:10.13798/j.issn.1009-153X.2017.06.017]
[5]呼铁民　褚会松　田　甜　王昆鹏　杨国军　杨立军　王维兴.脑胶质瘤ADAM17与EGFR的表达及临床意义[J].中国临床神经外科杂志,2017,(08):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
　HU Tie-min,CHU Hui-song,TIAN Tian,et al.Expressions of ADAM17 and EGFR in gliomas tissues and their clinical meanings[J].,2017,(01):557.[doi:10.13798/j.issn.1009-153X.2017.08.012]
[6]汪超甲 综述　王　辉 审校.脑胶质瘤化疗现状及耐药机制的研究进展[J].中国临床神经外科杂志,2017,(11):791.[doi:10.13798/j.issn.1009-153X.2017.11.023]
[7]高剑峰　姚庆和　李晓辉　龙宇波　陈振波.脑胶质瘤miR-9、PPARγ表达水平及临床意义[J].中国临床神经外科杂志,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
　GAO Jian-feng,YAO Qing-he,LI Xiao-hui,et al.Expressions of miR-9 and PPARγ in human brain gliomas and their clinical meanings[J].,2018,(01):17.[doi:10.13798/j.issn.1009-153X.2018.01.006]
[8]刘　靖　吴立权　黄书岚.聚焦解决模式对脑胶质瘤术后病人自我管理效能感及生命意义的影响[J].中国临床神经外科杂志,2018,(03):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
　LIU Jing,WU Li-quan,HUANG Shu-lan..Effects of solution focused intervention on self-management efficacy and meanings of life in the patients with gliomas after surgery[J].,2018,(01):208.[doi:10.13798/j.issn.1009-153X.2018.03.025]
[9]刘　炎　杭春华.脑胶质瘤卒中误诊为脑动静脉畸形并出血1例[J].中国临床神经外科杂志,2018,(06):448.[doi:10.13798/j.issn.1009-153X.2018.06.025]
[10]刘东明　胡新华　刘　永　陈　玖　刘宏毅.脑胶质瘤病人静息态默认模式网络研究进展[J].中国临床神经外科杂志,2018,(12):821.[doi:10.13798/j.issn.1009-153X.2018.12.022]

备注/Memo

备注/Memo:
（2022-12-28收稿，2023-01-09修回）
基金项目：新疆维吾尔自治区卫生计生委青年科技人才专项科研项目（wjwy201818）
通讯作者：秦　虎，E-mail：Qinhu86@163.con
更新日期/Last Update: 2022-02-28